Please login to the form below

Not currently logged in
Email:
Password:

Astellas picks PhRMA’s Uhlendorf for US public affairs lead

He will leave his role as VP, communications and public affairs at US trade body

Karl Uhlendorf_AstellasAstellas has named Karl Uhlendorf to lead public affairs efforts across its Americas business.

Uhlendorf, who joins Astellas on July 28, currently serves as VP, communications and public affairs at the US trade body the Pharmaceutical Research & Manufacturers of America (PhRMA).

In his new role as communications and advocacy director he will be responsible for strengthening Astellas' media and advocacy presence in Washington DC as well as providing strategic communications counsel to the Astellas' corporate communications and government affairs team.

Uhlendorf has significant experience in the area, having spent seven years at PhRMA in communications and public affairs roles.

Margaret Long, Astellas' VP, business communications and advocacy, said: "We are eager to leverage Karl's expertise in a number of key focus areas, namely media, public affairs and advocacy."

The company added that Uhlendorf's appointment was “the latest phase in the building of the new US corporate communications team”. Other recent appointments include former Lilly comms chief Jeff Winton as senior VP, chief communications officer.

27th June 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics